Press release Scar Treatment Market to Record an Exponential 3.4% CAGR by 2021 – 2031

The Scar Treatment Market is slated to reach US$ 16.7 Bn at a CAGR of 3.4% between 2021-2031. The present scenario is that of consumers driving as well as the accelerating pace of alteration in the healthcare vertical. This drives the digitally-enabled, seamlessly connected, and on-demand clinician-patient interactions. As such, patient-centric delivery transcending geographical barriers would be the epicenter going forward.

According to a revised report published by Persistence Market Research, the global scar treatment market valued at US$ 16.7 Bn in 2020, and is predicted to expand at a CAGR of around 3.4% over the forecast period (2021–2031).

Get Sample Copy of this Report
Scar treatment has been a rapid-growing industry, mainly due to increasing awareness regarding physical appearance. Rising occurrences of skin diseases, together with increasing awareness regarding different scar treatments, represent major factors boosting market growth.

Moreover, rise in the number of road accidents across the world is leading to increased number of surgeries, which later require scar treatment, where topical products are popular.

Company profiles:

Smith and Nephew plc.
Key Takeaways from Market Study

Topical scar products are expected to contribute more than 50% revenue share in the market by 2031.

Atrophic scars are expected to account for more than 45% of the global market share. These scars contribute 80% of the total scars that occur worldwide.

Among all the end-users, the hospital’s segment accounted for more than 37% of the market share in 2020, owing to technologically advanced treatments available at hospitals.

North America holds the highest share in the global scar treatment market, owing to a high number of road accidents and increasing utilization of cutting-edge scar treatment products in the country.

Key players are focused on strengthening their clinical pipelines through discoveries of novel abuse-deterrent formulations.

The U.S. holds a big portion of global revenue and accounts for more than 85% share in the North American market.
HRA Pharma
Sonoma Pharmaceuticals, Inc.
CCA Industries Inc.
Cynosure, Inc.
Avita Medical Limited
Mölnlycke Health Care AB
Pacific World Corporation
Shanghai Fosun Pharmaceuticals Ltd.
Beijing Toplaser Technology Company Limited
Bausch Health Companies Inc.

Leave a Reply